Meredith is a highly driven and dedicated health professional who thrives on delivering world class care to neuroendocrine cancer patients and enhancing the skills of other health professionals to deliver this care nationally and internationally. 

She has been involved in Oncology for over 40 years in metropolitan, rural, international, public, and private settings. 

Meredith joined NeuroEndocrine Cancer Australia (NECA) in 2018 in the role of national Project Officer / CRA / Telehealth Nurse. She has had principal roles in the writing of the NET GP / Nurse Education Modules and the NET Optimal Care Pathway. Meredith became the CEO of NECA in October 2022. Currently Meredith is on the Expert Advisory Group for the Australian Cancer Nurses Navigation program and the working group for Specialist Support Service. 

Areas of Advocacy in the past 18 months have been presenting at the Senate Inquiry for Equity of Access For Diagnostics and treatments for Rare and Less Common Cancers, Including Neuroendocrine Cancers and also lobbying for the Von Hippel Lindau community for the recommendation and listing of Belzutifan on the PBS.  

She is also Chair of the Finance and Risk Audit Committee and on the Board of Directors for Cancer Nurses Society of Australia (CNSA), Board of Directors for International NeuroEndocrine Cancer Alliance (INCA) President-Elect and Chair of the INCA Research Committee. 

Meredith Cummins has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies: